These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. How Does Shame Relate to Clinical and Psychosocial Outcomes in Knee Osteoarthritis? Yeo JY; Lim CJ; Yang SY; Tan BY Clin Orthop Relat Res; 2024 Dec; ():. PubMed ID: 39625176 [TBL] [Abstract][Full Text] [Related]
23. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661 [TBL] [Abstract][Full Text] [Related]
24. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
25. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714 [TBL] [Abstract][Full Text] [Related]
26. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; Miceli R; Di Bartolomeo M; Pietrantonio F Lancet Oncol; 2024 Dec; 25(12):1539-1550. PubMed ID: 39557058 [TBL] [Abstract][Full Text] [Related]
27. Tamoxifen for adults with hepatocellular carcinoma. Naing C; Ni H; Aung HH Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750 [TBL] [Abstract][Full Text] [Related]
28. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population. Chen BF; Tsai YF; Chao TC; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Lai JI; Tseng LM; Huang CC Clin Exp Med; 2024 Aug; 24(1):185. PubMed ID: 39133334 [TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy versus deferred treatment for localised prostate cancer. Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338 [TBL] [Abstract][Full Text] [Related]
30. High chromosomal instability is associated with higher 10-year risks of recurrence for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: clinical evidence from a large-scale, multiple-site, retrospective study. Liao YY; Fu J; Lu X; Qian Z; Yu Y; Zhu L; Pan JN; Li PC; Zhu QY; Li X; Sun W; Wang XJ; Cao WM J Pathol Clin Res; 2024 Nov; 10(6):e70011. PubMed ID: 39545625 [TBL] [Abstract][Full Text] [Related]
31. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. André F; Cortés J; Curigliano G; Modi S; Li W; Park YH; Chung WP; Kim SB; Yamashita T; Pedrini JL; Im SA; Tseng LM; Harbeck N; Krop I; Nakatani S; Tecson K; Ashfaque S; Egorov A; Hurvitz SA Ann Oncol; 2024 Dec; 35(12):1169-1180. PubMed ID: 39241960 [TBL] [Abstract][Full Text] [Related]
32. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication. Ryan R; Hill S Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081 [TBL] [Abstract][Full Text] [Related]
33. Methods of milk expression for lactating women. Becker GE; Smith HA; Cooney F Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006170. PubMed ID: 27684560 [TBL] [Abstract][Full Text] [Related]
34. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials. Wang Q; Yu J; Sun X; Li J; Cao S; Han Y; Wang H; Yang Z; Li J; Hu C; Zhang Y; Jin L Crit Rev Oncol Hematol; 2024 Dec; 204():104522. PubMed ID: 39332750 [TBL] [Abstract][Full Text] [Related]
35. Diabetes as a risk factor for tuberculosis disease. Franco JV; Bongaerts B; Metzendorf MI; Risso A; Guo Y; Peña Silva L; Boeckmann M; Schlesinger S; Damen JA; Richter B; Baddeley A; Bastard M; Carlqvist A; Garcia-Casal MN; Hemmingsen B; Mavhunga F; Manne-Goehler J; Viney K Cochrane Database Syst Rev; 2024 Aug; 8(8):CD016013. PubMed ID: 39177079 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881 [TBL] [Abstract][Full Text] [Related]
37. Drug therapy for obstructive sleep apnoea in adults. Mason M; Welsh EJ; Smith I Cochrane Database Syst Rev; 2013 May; 2013(5):CD003002. PubMed ID: 23728641 [TBL] [Abstract][Full Text] [Related]
38. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Gupta AA; Xue W; Harrison DJ; Hawkins DS; Dasgupta R; Wolden S; Shulkin B; Qumseya A; Routh JC; MacDonald T; Feinberg S; Crompton B; Rudzinski ER; Arnold M; Venkatramani R Lancet Oncol; 2024 Jul; 25(7):912-921. PubMed ID: 38936378 [TBL] [Abstract][Full Text] [Related]
39. A comparison of treatment allocation and survival between younger and older patients with HER2-overexpressing de novo metastatic breast cancer. Lemij A; de Glas N; Kroep J; Siesling S; van den Bos F; Bastiaannet E; Liefers GJ; Portielje J J Geriatr Oncol; 2024 Jul; 15(6):101805. PubMed ID: 38852378 [TBL] [Abstract][Full Text] [Related]